Marktanalyse - OTC Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide

OTC Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, China) OTC Pharmaceuticals industry. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

* Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights

Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the OTC pharmaceuticals industry and had a total market value of $22,484.3 million in 2010.

Russia was the fastest growing country with a CAGR of 10.3% over the 2006—10 period.

Within the OTC pharmaceuticals industry, China is the leading country among the BRIC nations with market revenues of $10,582.8 million in 2010.

China is expected to lead the OTC pharmaceuticals industry in the BRIC nations with a value of $14,378.8, million in 2015.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2010 annual average exchange rates.

TABLE OF CONTENTS

Introduction 10

What is this report about? 10

Who is the target reader? 10

How to use this report 10

Definitions 10

BRIC OTC Pharmaceuticals Industry Outlook 11

OTC Pharmaceuticals in Brazil 14

Market Overview 14

Market Data 15

Market Segmentation 16

Market outlook 21

Five forces analysis 22

Leading companies 28

Macroeconomic indicators 38

OTC Pharmaceuticals in China 40

Market Overview 40

Market Data 41

Market Segmentation 42

Market outlook 47

Five forces analysis 48

Leading companies 54

Macroeconomic indicators 60

OTC Pharmaceuticals in India 62

Market Overview 62

Market Data 63

Market Segmentation 64

Market outlook 69

Five forces analysis 70

Leading companies 76

Macroeconomic indicators 87

OTC Pharmaceuticals in Russia 89

Market Overview 89

Market Data 90

Market Segmentation 91

Market outlook 96

Five forces analysis 97

Leading companies 103

Macroeconomic indicators 112

Appendix 114

Methodology 114



LIST OF TABLES

Table 1:BRIC OTC pharmaceuticals industry, revenue($m), 2006—15 11

Table 2:BRIC OTC pharmaceuticals industry, revenue($m), 2006—10 12

Table 3:BRIC OTC pharmaceuticals industry, revenue($m), 2010—15 13

Table 4: Brazil OTC pharmaceuticals market value: $ million, 2006—10 15

Table 5: Brazil OTC pharmaceuticals market category segmentation: % share, by value, 2006—2010 16

Table 6: Brazil OTC pharmaceuticals market category segmentation: $ million, 2006-2010 16

Table 7: Brazil OTC pharmaceuticals market geography segmentation: $million, 2010 18

Table 8: Brazil OTC pharmaceuticals market share: % share, by value, 2010 19

Table 9: Brazil OTC pharmaceuticals market distribution: % share, by value, 2010 20

Table 10: Brazil OTC pharmaceuticals market value forecast: $ million, 2010—15 21

Table 11: Johnson & Johnson: key facts 28

Table 12: Johnson & Johnson: key financials ($) 29

Table 13: Johnson & Johnson: key financial ratios 30

Table 14: Sanofi-Aventis SA: key facts 32

Table 15: Sanofi-Aventis SA: key financials ($) 33

Table 16: Sanofi-Aventis SA: key financials (€) 33

Table 17: Sanofi-Aventis SA: key financial ratios 33

Table 18: Abbott Laboratories: key facts 35

Table 19: Abbott Laboratories: key financials ($) 36

Table 20: Abbott Laboratories: key financial ratios 36

Table 21: Brazil size of population (million), 2006—10 38

Table 22: Brazil gdp (constant 2000 prices, $ billion), 2006—10 38

Table 23: Brazil gdp (current prices, $ billion), 2006—10 38

Table 24: Brazil inflation, 2006—10 39

Table 25: Brazil consumer price index (absolute), 2006—10 39

Table 26: Brazil exchange rate, 2006—10 39

Table 27: China OTC pharmaceuticals market value: $ million, 2006—10 41

Table 28: China OTC pharmaceuticals market category segmentation: % share, by value, 2006—2010 42

Table 29: China OTC pharmaceuticals market category segmentation: $ million, 2006-2010 42

Table 30: China OTC pharmaceuticals market geography segmentation: $million, 2010 44

Table 31: China OTC pharmaceuticals market share: % share, by value, 2010 45

Table 32: China OTC pharmaceuticals market distribution: % share, by value, 2010 46

Table 33: China OTC pharmaceuticals market value forecast: $ million, 2010—15 47

Table 34: Johnson & Johnson: key facts 54

Table 35: Johnson & Johnson: key financials ($) 55

Table 36: Johnson & Johnson: key financial ratios 56

Table 37: Chengdu Rosun Antiseptic Pharmaceutical Co., Ltd.: key facts 58

Table 38: Huangshan Tianmu Pharmaceutical Co., Ltd.: key facts 59

Table 39: China size of population (million), 2006—10 60

Table 40: China gdp (constant 2000 prices, $ billion), 2006—10 60

Table 41: China gdp (current prices, $ billion), 2006—10 60

Table 42: China inflation, 2006—10 61

Table 43: China consumer price index (absolute), 2006—10 61

Table 44: China exchange rate, 2006—10 61

Table 45: India OTC pharmaceuticals market value: $ million, 2006—10 63

Table 46: India OTC pharmaceuticals market category segmentation: % share, by value, 2006—2010 64

Table 47: India OTC pharmaceuticals market category segmentation: $ million, 2006-2010 64

Table 48: India OTC pharmaceuticals market geography segmentation: $million, 2010 66

Table 49: India OTC pharmaceuticals market share: % share, by value, 2010 67

Table 50: India OTC pharmaceuticals market distribution: % share, by value, 2010 68

Table 51: India OTC pharmaceuticals market value forecast: $ million, 2010—15 69

Table 52: Cipla Ltd: key facts 76

Table 53: Cipla Ltd: key financials ($) 77

Table 54: Cipla Ltd: key financials (Rs.) 78

Table 55: Cipla Ltd: key financial ratios 78

Table 56: Johnson & Johnson: key facts 80

Table 57: Johnson & Johnson: key financials ($) 81

Table 58: Johnson & Johnson: key financial ratios 82

Table 59: GlaxoSmithKline Plc: key facts 84

Table 60: GlaxoSmithKline Plc: key financials ($) 85

Table 61: GlaxoSmithKline Plc: key financials (£) 85

Table 62: GlaxoSmithKline Plc: key financial ratios 85

Table 63: India size of population (million), 2006—10 87

Table 64: India gdp (constant 2000 prices, $ billion), 2006—10 87

Table 65: India gdp (current prices, $ billion), 2006—10 87

Table 66: India inflation, 2006—10 88

Table 67: India consumer price index (absolute), 2006—10 88

Table 68: India exchange rate, 2006—10 88

Table 69: Russia OTC pharmaceuticals market value: $ million, 2006—10 90

Table 70: Russia OTC pharmaceuticals market category segmentation: % share, by value, 2006—2010 91

Table 71: Russia OTC pharmaceuticals market category segmentation: $ million, 2006-2010 91

Table 72: Russia OTC pharmaceuticals market geography segmentation: $million, 2010 93

Table 73: Russia OTC pharmaceuticals market share: % share, by value, 2010 94

Table 74: Russia OTC pharmaceuticals market distribution: % share, by value, 2010 95

Table 75: Russia OTC pharmaceuticals market value forecast: $ million, 2010—15 96

Table 76: Sanofi-Aventis SA: key facts 103

Table 77: Sanofi-Aventis SA: key financials ($) 104

Table 78: Sanofi-Aventis SA: key financials (€) 104

Table 79: Sanofi-Aventis SA: key financial ratios 104

Table 80: Johnson & Johnson: key facts 106

Table 81: Johnson & Johnson: key financials ($) 107

Table 82: Johnson & Johnson: key financial ratios 108

Table 83: Menarini Group, The: key facts 110

Table 84: Russia size of population (million), 2006—10 112

Table 85: Russia gdp (constant 2000 prices, $ billion), 2006—10 112

Table 86: Russia gdp (current prices, $ billion), 2006—10 112

Table 87: Russia inflation, 2006—10 113

Table 88: Russia consumer price index (absolute), 2006—10 113

Table 89: Russia exchange rate, 2006—10 113



LIST OF FIGURES

Figure 1: BRIC OTC pharmaceuticals industry, revenue($m), 2006—15 11

Figure 2: BRIC OTC pharmaceuticals industry, revenue($m), 2006—10 12

Figure 3: BRIC OTC pharmaceuticals industry, revenue($m), 2010—15 13

Figure 4: Brazil OTC pharmaceuticals market value: $ million, 2006—10 15

Figure 5: Brazil OTC pharmaceuticals market category segmentation: $ million, 2006-2010 17

Figure 6: Brazil OTC pharmaceuticals market geography segmentation: % share, by value, 2010 18

Figure 7: Brazil OTC pharmaceuticals market share: % share, by value, 2010 19

Figure 8: Brazil OTC pharmaceuticals market distribution: % share, by value, 2010 20

Figure 9: Brazil OTC pharmaceuticals market value forecast: $ million, 2010—15 21

Figure 10: Forces driving competition in the OTC pharmaceuticals market in Brazil, 2010 22

Figure 11: Drivers of buyer power in the OTC pharmaceuticals market in Brazil, 2010 23

Figure 12: Drivers of supplier power in the OTC pharmaceuticals market in Brazil, 2010 24

Figure 13: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Brazil, 2010 25

Figure 14: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Brazil, 2010 26

Figure 15: Drivers of degree of rivalry in the OTC pharmaceuticals market in Brazil, 2010 27

Figure 16: Johnson & Johnson: revenues & profitability 30

Figure 17: Johnson & Johnson: assets & liabilities 31

Figure 18: Sanofi-Aventis SA: revenues & profitability 34

Figure 19: Sanofi-Aventis SA: assets & liabilities 34

Figure 20: Abbott Laboratories: revenues & profitability 37

Figure 21: Abbott Laboratories: assets & liabilities 37

Figure 22: China OTC pharmaceuticals market value: $ million, 2006—10 41

Figure 23: China OTC pharmaceuticals market category segmentation: $ million, 2006-2010 43

Figure 24: China OTC pharmaceuticals market geography segmentation: % share, by value, 2010 44

Figure 25: China OTC pharmaceuticals market share: % share, by value, 2010 45

Figure 26: China OTC pharmaceuticals market distribution: % share, by value, 2010 46

Figure 27: China OTC pharmaceuticals market value forecast: $ million, 2010—15 47

Figure 28: Forces driving competition in the OTC pharmaceuticals market in China, 2010 48

Figure 29: Drivers of buyer power in the OTC pharmaceuticals market in China, 2010 49

Figure 30: Drivers of supplier power in the OTC pharmaceuticals market in China, 2010 50

Figure 31: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in China, 2010 51

Figure 32: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in China, 2010 52

Figure 33: Drivers of degree of rivalry in the OTC pharmaceuticals market in China, 2010 53

Figure 34: Johnson & Johnson: revenues & profitability 56

Figure 35: Johnson & Johnson: assets & liabilities 57

Figure 36: India OTC pharmaceuticals market value: $ million, 2006—10 63

Figure 37: India OTC pharmaceuticals market category segmentation: $ million, 2006-2010 65

Figure 38: India OTC pharmaceuticals market geography segmentation: % share, by value, 2010 66

Figure 39: India OTC pharmaceuticals market share: % share, by value, 2010 67

Figure 40: India OTC pharmaceuticals market distribution: % share, by value, 2010 68

Figure 41: India OTC pharmaceuticals market value forecast: $ million, 2010—15 69

Figure 42: Forces driving competition in the OTC pharmaceuticals market in India, 2010 70

Figure 43: Drivers of buyer power in the OTC pharmaceuticals market in India, 2010 71

Figure 44: Drivers of supplier power in the OTC pharmaceuticals market in India, 2010 72

Figure 45: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in India, 2010 73

Figure 46: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in India, 2010 74

Figure 47: Drivers of degree of rivalry in the OTC pharmaceuticals market in India, 2010 75

Figure 48: Cipla Ltd: revenues & profitability 78

Figure 49: Cipla Ltd: assets & liabilities 79

Figure 50: Johnson & Johnson: revenues & profitability 82

Figure 51: Johnson & Johnson: assets & liabilities 83

Figure 52: GlaxoSmithKline Plc: revenues & profitability 86

Figure 53: GlaxoSmithKline Plc: assets & liabilities 86

Figure 54: Russia OTC pharmaceuticals market value: $ million, 2006—10 90

Figure 55: Russia OTC pharmaceuticals market category segmentation: $ million, 2006-2010 92

Figure 56: Russia OTC pharmaceuticals market geography segmentation: % share, by value, 2010 93

Figure 57: Russia OTC pharmaceuticals market share: % share, by value, 2010 94

Figure 58: Russia OTC pharmaceuticals market distribution: % share, by value, 2010 95

Figure 59: Russia OTC pharmaceuticals market value forecast: $ million, 2010—15 96

Figure 60: Forces driving competition in the OTC pharmaceuticals market in Russia, 2010 97

Figure 61: Drivers of buyer power in the OTC pharmaceuticals market in Russia, 2010 98

Figure 62: Drivers of supplier power in the OTC pharmaceuticals market in Russia, 2010 99

Figure 63: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Russia, 2010 100

Figure 64: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Russia, 2010 101

Figure 65: Drivers of degree of rivalry in the OTC pharmaceuticals market in Russia, 2010 102

Figure 66: Sanofi-Aventis SA: revenues & profitability 105

Figure 67: Sanofi-Aventis SA: assets & liabilities 105

Figure 68: Johnson & Johnson: revenues & profitability 108

Figure 69: Johnson & Johnson: assets & liabilities 109

• OTC Triptans in Norway
• OTC Triptans in Azerbaijan
• OTC Triptans in Kazakhstan
• OTC Triptans in Sweden
• Calming and Sleeping in Australia
• Calming and Sleeping in Croatia
• Cough, Cold and Allergy (Hay Fever) Remedies in Australia
• Cough, Cold and Allergy (Hay Fever) Remedies in Croatia
• Over-the-counter Pharmaceuticals Market in the Asia Pacific Region 2012-2016
• Over-the-counter Pharmaceuticals Market in the Asia Pacific Region 2012-2016
• Global Over-the-counter Pharmaceutical Market 2012-2016
• OTC Pharmaceuticals and Self-medication in Seven Emerging Markets
• OTC Triptans in Germany
• OTC Triptans in Sweden
• OTC Triptans in the United Kingdom
• Cough, Cold and Allergy (Hay Fever) Remedies in the US
• Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
• Global OTC Pharmaceuticals
• OTC Pharmaceuticals - Global Group of Eight (G8) Industry Guide
• OTC Pharmaceuticals - North America (NAFTA) Industry Guide